Sugi Predict

Sugi Predict / Compounds / SCHEMBL1443345

SCHEMBL1443345

SCHEMBL1443345

O=C(N[C@@H](Cc1ccccc1)C(=O)N1CCC[C@H]1C(=O)c1nc2ccccc2s1)OCc1ccccc1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ACE P12821 7/20 0.54
▸ REN P00797 1/20 0.48
▸ F2 P00734 1/20 0.46
▸ CTRB1 P17538 1/20 0.46
▸ ACE2 Q9BYF1 4/20 0.46
▸ PREP P48147 2/20 0.44
▸ DPP4 P27487 1/20 0.43
▸ DPP8 Q6V1X1 1/20 0.43
▸ HDAC3 O15379 1/20 0.43
▸ HDAC4 P56524 1/20 0.43
▸ HDAC1 Q13547 1/20 0.43
▸ HDAC7 Q8WUI4 1/20 0.43
▸ HDAC2 Q92769 1/20 0.43
▸ HDAC10 Q969S8 1/20 0.43
▸ HDAC11 Q96DB2 1/20 0.43
▸ HDAC8 Q9BY41 1/20 0.43
▸ HDAC6 Q9UBN7 1/20 0.43
▸ HDAC9 Q9UKV0 1/20 0.43
▸ HDAC5 Q9UQL6 1/20 0.43
▸ ITGB3 P05106 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13475725 1.00 ACE (0.54) ACERENF2CTRB1ACE2
SCHEMBL8230028 1.00 ACE (0.54) ACERENF2CTRB1ACE2
SCHEMBL8264388 0.93 ACE (0.47) ACERENF2ACE2PREP
SCHEMBL13409464 0.90 F2 (0.46) ACERENF2ACE2
SCHEMBL13475726 0.89 PREP (0.57) ACERENF2CTRB1PREP
SCHEMBL13409456 0.89 PREP (0.57) ACERENF2CTRB1PREP
SCHEMBL8263227 0.89 DPP4 (0.58) ACEDPP4DPP8HDAC3HDAC4
SCHEMBL8263228 0.89 ACE (0.55) ACEF2
SCHEMBL13409461 0.86 DPP4 (0.46) ACEF2DPP4DPP8HDAC3
SCHEMBL8079479 0.84 PREP (0.55) CTRB1PREP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 128 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11339152-B2 Inhibitors VIVORYON THERAPEUTICS N.V. 2022-05-24 — — US disclosed
US-20200377493-A1 NOVEL INHIBITORS VIVORYON THERAPEUTICS N.V. (DE) 2020-12-03 — — US disclosed
US-20200223825-A1 INHIBITORS OF GLUTAMINYL CYCLASE VIVORYON THERAPEUTICS N.V (DE) 2020-07-16 — — US disclosed
EP-3461819-B1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2020-05-27 — — EP disclosed
EP-3601269-A1 NOVEL INHIBITORS Probiodrug AG (DE) 2020-02-05 — — EP disclosed
EP-2970235-B1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2019-06-19 — — EP disclosed
WO-2019063414-A1 INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2019-04-04 — — WO disclosed
EP-3461819-A1 INHIBITORS OF GLUTAMINYL CYCLASE Probiodrug AG (DE) 2019-04-03 — — EP disclosed
WO-2018178384-A1 NOVEL INHIBITORS PROBIODRUG AG (DE) 2018-10-04 — — WO disclosed
US-9656991-B2 Inhibitors of glutaminyl cyclase PROBIODRUG AG (DE) 2017-05-23 — — US disclosed
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-09-11 — — US disclosed
US-20080214620-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-09-04 — — US disclosed
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase PROBIODRUG AG (DE) 2008-08-28 — — US disclosed
WO-2008065141-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-06-05 — — WO disclosed
WO-2008055945-A1 3-HYDR0XY-1,5-DIHYDR0-PYRR0L-2-ONE DERIVATIVES AS INHIBITORS OF GLUTAMINYL CYCLASE FOR THE TREATMENT OF ULCER, CANCER AND OTHER DISEASES PROBIODRUG AG (DE) 2008-05-15 — — WO disclosed
WO-2008055947-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-05-15 — — WO disclosed
WO-2008055950-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE PROBIODRUG AG (DE) 2008-05-15 — — WO disclosed
US-20070244177-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 — — US disclosed
WO-2007116092-A1 ENZYME INHIBITORS PROBIODRUG AG (DE) 2007-10-18 — — WO disclosed
US-20070191366-A1 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES PROBIODRUG AG (DE) 2007-08-16 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070191366-A1 USE OF EFFECTORS OF GLUTAMINYL AND GLUTAMATE CYCLASES GLS, QPCT, GLS2 ACE 2722/4885REN 3035/4885F2 3527/4885
US-20080214620-A1 NOVEL INHIBITORS OF GLUTAMINYL CYCLASE GLS, GLS2, GLUL ACE 2580/4885REN 1269/4885F2 4215/4885
US-20070244177-A1 ENZYME INHIBITORS ACHE, BACE1, MAOA ACE 6/4885REN 595/4885F2 639/4885
US-20200377493-A1 NOVEL INHIBITORS GLUL, GLS, QPCT ACE 714/4885REN 1147/4885F2 1107/4885
US-20200223825-A1 INHIBITORS OF GLUTAMINYL CYCLASE QPCT, QPCTL, GLUL ACE 1103/4885REN 1136/4885F2 1326/4885
US-20080221086-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL ACE 795/4885REN 401/4885F2 4318/4885
US-11339152-B2 Inhibitors GLUL, QPCT, GLS ACE 747/4885REN 1205/4885F2 947/4885
US-20080207715-A1 Novel Inhibitors of Glutaminyl Cyclase GLS, GLS2, GLUL ACE 1261/4885REN 1460/4885F2 4543/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.